Jason joined Sofinnova as an Associate in 2018. In 2019, he was promoted to Principal. He focuses on therapeutics investments. Jason led the investment in Karuna and serves as a board observer for Velos Biopharma and Cincor Pharma.
Prior to joining Sofinnova, Jason was a consultant with McKinsey & Company, focusing primarily on operational and strategic R&D issues for top companies in pharmaceuticals and medical products. Before transitioning to consulting, Jason studied the genetic mechanisms of neurodegenerative disease as a graduate student at The Rockefeller University in the lab of Dr. Marc Tessier-Lavigne, founder of Denali Therapeutics and current Stanford University president. Prior to enrolling at Rockefeller, Jason worked as a research associate at Regeneron Pharmaceuticals, Inc.
Jason received his PhD in Neuroscience from The Rockefeller University, where he was awarded The David Rockefeller Fellowship. Jason also holds a BS in Neurobiology and Behavior from Cornell University.